Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.
Poolbeg is a clinical-stage infectious disease pharmaceutical company based in London.
The company’s consortium, EncOVac, has been awarded €2.3 million from the Irish Government’s Disruptive Technologies Innovation Fund to progress its oral vaccine platform.
Poolbeg is collaborating with University College Dublin, Trinity College Dublin and AnaBio Technologies over three years to develop an oral vaccine candidate to a phase I ready state.
The company said that the resulting technology will serve as a platform for additional oral vaccine candidates for a range of pathogens, initially targeting bacterial infections.
Luke O’Neill, Project Advisory Board chair at Trinity College Dublin, said: ‘Oral vaccines are currently only available to treat a small number of pathogens and a more comprehensive approach to vaccine development is needed to design new, safe, and effective oral vaccines. Such a system would revolutionise our approach to protecting people from infectious diseases.’
Poolbeg shares closed up 6.0% at 9.80 pence on Tuesday afternoon in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
